Johnson & Johnson (JNJ) Rating Reiterated by Bank of America Corp.
Johnson & Johnson (NYSE:JNJ)‘s stock had its “hold” rating reissued by analysts at Bank of America Corp. in a report released on Monday. They presently have a $126.00 target price on the stock. Bank of America Corp.’s price target suggests a potential upside of 12.02% from the stock’s previous close.
Several other equities research analysts also recently commented on the stock. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 target price on the stock in a research report on Monday, August 22nd. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price on the stock in a research report on Friday, August 5th. BTIG Research reiterated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, September 7th. RBC Capital Markets set a $133.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Wednesday, November 9th. Finally, Credit Suisse Group AG reiterated a “neutral” rating and set a $123.00 target price on shares of Johnson & Johnson in a research report on Monday, September 19th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $121.03.
Johnson & Johnson (NYSE:JNJ) opened at 112.48 on Monday. The firm has a market capitalization of $306.01 billion, a price-to-earnings ratio of 19.74 and a beta of 0.75. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The company has a 50-day moving average of $115.85 and a 200 day moving average of $118.43.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.66 by $0.02. The company had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The firm’s revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.49 EPS. On average, analysts anticipate that Johnson & Johnson will post $6.72 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date is Friday, November 18th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.29. Johnson & Johnson’s payout ratio is presently 56.64%.
In related news, Director Charles Prince bought 875 shares of the company’s stock in a transaction that occurred on Friday, October 21st. The shares were bought at an average price of $114.11 per share, for a total transaction of $99,846.25. Following the transaction, the director now directly owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.11% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Avalon Advisors LLC raised its stake in shares of Johnson & Johnson by 32.7% in the first quarter. Avalon Advisors LLC now owns 410,880 shares of the company’s stock worth $44,457,000 after buying an additional 101,250 shares during the period. Fundsmith LLP raised its stake in shares of Johnson & Johnson by 24.1% in the second quarter. Fundsmith LLP now owns 3,704,693 shares of the company’s stock worth $449,379,000 after buying an additional 719,532 shares during the period. Shelton Capital Management raised its stake in shares of Johnson & Johnson by 17.5% in the second quarter. Shelton Capital Management now owns 58,181 shares of the company’s stock worth $7,057,000 after buying an additional 8,669 shares during the period. British Columbia Investment Management Corp raised its stake in shares of Johnson & Johnson by 1.0% in the second quarter. British Columbia Investment Management Corp now owns 1,649,232 shares of the company’s stock worth $200,052,000 after buying an additional 17,000 shares during the period. Finally, RKL Wealth Management LLC raised its stake in shares of Johnson & Johnson by 16.7% in the second quarter. RKL Wealth Management LLC now owns 43,943 shares of the company’s stock worth $5,167,000 after buying an additional 6,287 shares during the period. Institutional investors own 64.13% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.